ALEC on Nasdaq
Alector (United States)
Company in San Francisco, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2013Founded1
Compare with LENZ Therapeutics, Inc., Cullinan Oncology or Metagenomi Therapeutics, Inc., or pick any stock.
- TickerALEC on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- Websitewww.alector.com
- Business address131 Oyster Point Blvd., Suite 600, South San Francisco, Ca 940803
- Filer categoryAccelerated filer, Smaller reporting company3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-741.3%Operating margin4
-679.2%Net margin4
-79.1%Revenue growth, 20254
-466.3%Return on equity4
0.30×Debt to equity4
-$184.1MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$123.1M
- Income tax0¢$168.0K
Out of $21.0M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration revenue | $21.0M | $100.6M |
| Research and development | $123.1M | $185.9M |
| General and administrative | $54.0M | $59.6M |
| Total operating expenses | $177.1M | $245.6M |
| Loss from operations | -$156.0M | -$145.0M |
| Other income, net | $13.2M | $26.1M |
| Loss before income taxes | -$142.8M | -$118.9M |
| Income tax expense | $168.0K | $128.0K |
| Net loss | -$142.9M | -$119.0M |
| Unrealized gain (loss) on marketable securities | -$95.0K | $77.0K |
| Comprehensive loss | -$143.0M | -$119.0M |
| Net loss per share, basic | -$1.39 | -$1.23 |
| Net loss per share, diluted | -$1.39 | -$1.23 |
| Shares used in computing net loss per share, basic | 103.0M shares | 96.6M shares |
| Shares used in computing net loss per share, diluted | 103.0M shares | 96.6M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $65.8M | $33.0M | |
| Marketable securities | $190.2M | $380.4M | |
| Prepaid expenses and other current assets | $10.4M | $11.4M | |
| Total current assets | $266.5M | $424.8M | |
| Property and equipment, net | $10.8M | $17.1M | |
| Operating lease right-of-use assets | $13.7M | $20.0M | |
| Restricted cash | $1.8M | $1.8M | |
| Other assets | $386.0K | $4.5M | |
| Total assets | $293.2M | $468.3M | |
| Accounts payable | $1.7M | $2.2M | |
| Accrued clinical supply costs | $3.7M | $7.0M | |
| Accrued liabilities | $19.3M | $28.9M | |
| Deferred revenue, current portion | $6.7M | $23.7M | |
| Payable to collaboration partner | $17.3M | $5.9M | |
| Refund liability to collaboration partner, current portion | $11.4M | $48.6M | |
| Operating lease liabilities, current portion | $9.1M | $8.8M | |
| Short-term debt | $366.0K | $0 | |
| Total current liabilities | $69.5M | $125.1M | |
| Deferred revenue, long-term portion | $164.5M | $172.2M | |
| Long-term debt | $9.3M | $9.4M | |
| Refund liability to collaboration partner, long-term portion | $0 | $9.3M | |
| Operating lease liabilities, long-term portion | $17.5M | $24.4M | |
| Other long-term liabilities | $1.7M | $1.2M | |
| Total liabilities | $262.6M | $341.5M | |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 110,362,581 and 99,085,888 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $11.0K | $9.0K | |
| Additional paid-in capital | $1.0B | $955.7M | |
| Accumulated other comprehensive income | $166.0K | $261.0K | |
| Accumulated deficit | -$972.1M | -$829.1M | |
| Total stockholders' equity | $30.6M | $126.8M | $134.2M |
| Total liabilities and stockholders' equity | $293.2M | $468.3M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 110.4M shares | 99.1M shares | |
| Common stock, shares outstanding | 110.4M shares | 99.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$142.9M | -$119.0M |
| Depreciation and amortization | $5.7M | $5.4M |
| Stock-based compensation | $26.7M | $39.5M |
| Amortization of premiums and accretion of discounts on marketable securities | -$6.6M | -$14.4M |
| Amortization of right-of-use assets | $3.9M | $3.4M |
| Amortization of debt discount and debt issuance costs | $293.0K | |
| Impairment loss of right-of-use assets and leasehold improvements | $2.9M | $2.2M |
| Prepaid expenses and other current assets | $992.0K | $5.5M |
| Other assets | $4.2M | $2.9M |
| Accounts payable | -$524.0K | -$1.4M |
| Accrued liabilities and accrued clinical supply costs | -$12.9M | $340.0K |
| Payable to collaboration partner | $11.4M | -$1.8M |
| Deferred revenue | -$21.0M | -$100.6M |
| Refund liability to collaboration partner | -$50.0M | -$46.0M |
| Lease liabilities | -$6.6M | -$5.8M |
| Other long-term liabilities | $503.0K | -$139.0K |
| Net cash used in operating activities | -$184.0M | -$229.9M |
| Purchase of property and equipment | -$41.0K | -$1.3M |
| Purchase of marketable securities | -$271.9M | -$467.7M |
| Maturities of marketable securities | $465.5M | $573.6M |
| Sale of marketable securities | $3.0M | $2.6M |
| Net cash provided by investing activities | $196.6M | $107.1M |
| Proceeds from the exercise of options to purchase common stock | $15.0K | $0 |
| Proceeds from issuance of stock from employee stock purchase plan | $217.0K | $1.0M |
| Proceeds from issuance of common stock, net of issuance costs | $20.0M | $71.1M |
| Proceeds from debt financing, net of discount and issuance costs | $0 | $9.4M |
| Net cash provided by financing activities | $20.2M | $81.5M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $32.8M | -$41.2M |
| Interest paid | $855.0K | $0 |
Former names
- Alector LLCSep 16, 2015 to Sep 16, 20153
Timeline
- 2013Founded Founded1
Recent filings
- Oct 14, 20268-K
- Oct 5, 20268-K
- Sep 18, 2026SCHEDULE 13G
- Sep 4, 2026144
- Sep 4, 20264
- Sep 4, 20264
- Sep 4, 20264
- Sep 2, 2026144
- Sep 1, 2026144
- Sep 1, 2026144
- Sep 1, 2026144
- Aug 21, 20264
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jul 9, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.alector.com1
- WikidataQ61934361
- SEC EDGARCIK 1653087
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11